At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Giovanni Luca Ceresoli, Head of Pneumology and Oncology Urological Hospital Humanitas Gavazzeni Section, delivered a talk on “The Current State of Renal Oncology in Italy”.
Dr. Ceresoli outlined how renal cancer incidence in Italy is rising, with over 13,000 new cases annually, though survival has improved in recent years thanks to advances in imaging, surgery, targeted therapies, and immunotherapy. He emphasized the benefits of robotic and minimally invasive surgery in preserving kidney function, and the growing role of ablative techniques for patients not suitable for surgery.
He also highlighted the impact of clinical trials, including KEYNOTE-564, which led to the approval of adjuvant pembrolizumab in Italy in 2025. However, he noted challenges such as uneven access to specialized care, the need for better referral pathways, and the importance of centralizing expertise to deliver high-quality care across the country.
Join us in this conversation.